Indiana companies prepping for burst of acquisitions
Conditions are ripe for a barrage of mergers and acquisitions to take place this year.
Eli Lilly and Co.
Articles
DeCoudreaux leaving Lilly for top job at Mills College
Alecia DeCoudreaux, the top attorney for Eli Lilly and Co.’s U.S. unit and an active community volunteer, will leave to become president of Mills College in California on July 1.
Carmel firm gets FDA approval for lice treatment
ParaPRO LLC’s treatment, called Natroba, has a potential U.S. market of 6 million to 12 million infected children annually.
Down on luck, Lilly finds comfort in pets
Eli Lilly and Co. continues to misfire on getting new human medicines approved, but its animal health unit is on a roll.
Lilly imaging drug isn’t ready for approval, FDA says
Eli Lilly and Co.’s experimental drug to help identify plaque in the brain tied to Alzheimer’s disease isn’t ready for approval, according to U.S. regulators.
Panel says Lilly’s Solpura isn’t ready for approval
Eli Lilly and Co. failed to win an FDA advisory panel’s recommendation to introduce the first pancreatic enzyme that isn’t derived from pig parts.
Deal could give Lilly full diabetes deck
Eli Lilly and Co.’s diabetes partnership with Boehringer Ingelheim GmbH represents a new kind of disease-focused strategy that some consultants think is key to pharma companies’ futures.
UPDATE: Analysts praise Lilly diabetes deal with Boehringer
The deal Eli Lilly and Co. announced Tuesday morning with Boehringer Ingelheim GmbH sounded a lot like a baseball trade—with five drugs and payments to be named later—but analysts and investors generally liked what they heard.
Lilly agrees to pay up to $1.2B for diabetes drugs
A complex deal with Boehringer Ingelheim also gives the German company rights to two experimental Lilly insulins.
Lilly’s Solpura may lack data to prove effectiveness
Outside advisers to the FDA will meet Jan. 12 to review whether the drug should be approved for people with pancreas insufficiency caused by cystic fibrosis, chronic pancreatitis or other conditions.
Lilly bumped up federal lobbying in third quarter
The Indianapolis-based drugmaker spent $2.1 million in the three months that ended Sept. 30, a 5-percent increase from the same quarter last year and a jump of more than 30 percent from the $1.6 million it spent in this year's second quarter.
Lilly, other big drugmakers shut out by FDA in 2010
Regulators cleared 21 medicines, the fewest since 2007, for sale last year. It was the first time in a decade that Pfizer Inc., the world’s largest drugmaker, as well as Lilly, Merck & Co. and Bristol-Myers Squibb Co. were shut out at the same time, according to agency records.
Roche acquires Marcadia Biotech
Marcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in 2006, has been acquired by Swiss life sciences giant Roche.
Amylin and Lilly seek expanded Byetta approval
Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Wednesday they are asking the Food and Drug Administration to expand approval for their type 2 diabetes drug Byetta, which could bolster sales as the companies try to get approval for a new, longer-lasting version of the drug.
Eli Lilly puts faith in drug pipeline
Eli Lilly and Co. started to tip over its massive “patent cliff” this year, yet announced little publicly that will significantly soften its inevitable sales plunge.
Lilly Alzheimer’s imaging agent to get priority FDA review
Eli Lilly and Co. said the Food and Drug Administration will perform a faster review of florbetapir, an imaging agent that may help diagnose Alzheimer's disease.
Lilly suspends late-stage trial for melanoma drug
Eli Lilly and Co. suspended a late-stage clinical trial of a medicine for skin-cancer patients after 12 patients in the study died.
Contrarians think it’s new day for Lilly
The trouble-free market approval obtained by Eli Lilly and Co. for a new underarm testosterone treatment brightened the company’s outlook—at least for one of the few optimistic analysts covering the company.
Lilly, Acrux receive FDA approval for Axiron
The companies believe the underarm testosterone solution has the potential to realize sales of more than $1 billion a year in the United States.
Lilly scores series of small victories
The Indianapolis-based drugmaker finally won FDA approval for its antidepressant Cymbalta to treat chronic pain and fended off a patent challenge to rising-star cancer drug Alimta, but got a ratings downgrade on its debt.